Remibrutinib Label Expansion and Exosome Advances Headline Dermatology Times Coverage
Dermatology Times flags a remibrutinib label expansion and exosome progress, but the syndicated text names no trials, indications, or dates. Here is what holds up.
Topic
Chronic Spontaneous Urticaria
Topic
Chronic Spontaneous Urticaria
Remibrutinib Approval Marks First On-Label Dermographism Drug
Remibrutinib's FDA approval delivers the first on-label systemic therapy for symptomatic dermographism, ending decades of off-lab…
Barzolvolimab Hits All Phase 3 End Points in Chronic Spontaneous Urticaria
Barzolvolimab, a KIT-targeting monoclonal antibody, met all primary and secondary end points in a Phase 3 chronic spontaneous urt…